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Abstract
Muscle wasting is a common feature of inflammatory myopathies. Glucocorticoids (GCs), although effective at
suppressing inflammation and inflammatory muscle loss, also cause myopathy with prolonged administration.
11-Hydroxysteroid dehydrogenase type 1 (11-HSD1) is a bidirectional GC-activating enzyme that is potently
upregulated by inflammation within mesenchymal-derived tissues. We assessed the regulation of this enzyme with
inflammation in muscle, and examined its functional impact on muscle. The expression of 11-HSD1 in response
to proinflammatory stimuli was determined in a transgenic murine model of chronic inflammation (TNF-Tg)
driven by overexpression of tumour necrosis factor (TNF)- within tissues, including muscle. The inflammatory
regulation and functional consequences of 11-HSD1 expression were examined in primary cultures of human and
murine myotubes and human and murine muscle biopsies ex vivo. The contributions of 11-HSD1 to muscle
inflammation and wasting were assessed in vivo with the TNF-Tg mouse on an 11-HSD1 null background.
11-HSD1 was significantly upregulated within the tibialis anterior and quadriceps muscles from TNF-Tg mice.
In human and murine primary myotubes, 11-HSD1 expression and activity were significantly increased in
response to the proinflammatory cytokine TNF- (mRNA, 7.6-fold, p< 0.005; activity, 4.1-fold, p< 0.005).
Physiologically relevant levels of endogenous GCs activated by 11-HSD1 suppressed proinflammatory cytokine
output (interkeukin-6, TNF-, and interferon-), but had little impact on markers of muscle wasting in human
myotube cultures. TNF-Tg mice on an 11-11-HSD1 knockout background developed greater muscle wasting
than their TNF-Tg counterparts (27.4% less; p< 0.005), with smaller compacted muscle fibres and increased
proinflammatory gene expression relative to TNF-Tg mice with normal 11-HSD1 activity. This study demonstrates
that inflammatory stimuli upregulate 11-HSD1 expression and GC activation within muscle. Although concerns
have been raised that excess levels of GCs may be detrimental to muscle, in this inflammatory TNF--driven
model, local endogenous GC activation appears to be an important anti-inflammatory response that protects
against inflammatory muscle wasting in vivo.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Glucocorticoids (GCs) are highly effective in the treat-
ment of chronic inflammatory myopathies, controlling
inflammation and protecting against muscle wasting and
associated weakness [1]. Similar beneficial effects are
observed in patients with Duchennemuscular dystrophy,
who develop progressive muscle wasting driven by mus-
cle fibre necrosis, and in whom therapeutic GCs improve
muscle strength and functional outcomes [2–6]. The
mechanisms behind these beneficial features of thera-
peutic GCs are not fully understood; however, inhibi-
tion of muscle inflammation, reduced fibre necrosis and
increased myogenesis have been reported [7–9].
Unfortunately, prolonged exposure to therapeutic
GCs is complicated by side effects, including myopathy
that is mediated through inhibition of myogenesis,
catabolic breakdown of muscle protein via suppression
of insulin-like growth factor 1 (IGF-1), and increased
proteolysis and atrophy of muscle fibres [10–13]. In
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
11𝛃HSD1 protects against local inflammation within muscle 473
many tissues, both the beneficial and detrimental effects
of GCs have been explained by tissue-specific targeting
of their effects by 11β-hydroxysteroid dehydrogenase
type 1 (11β-HSD1). This bidirectional enzyme pri-
marily activates GCs [cortisone to cortisol in humans;
11-dehydrocorticosterone (DHC) to corticosterone in
mice] in vivo, and is a key determinant of exogenous
GC effects in muscle, adipose tissue, liver and skin in
mice [14].
11β-HSD1 is present and biologically active in
human skeletal muscle and in primary mesenchymal
cell cultures derived from it, where it is implicated in
GC-induced muscle wasting [15–20]. We have previ-
ously demonstrated that mesenchymal cells, including
osteoblasts, adipocytes, and fibroblasts, significantly
upregulate 11β-HSD1 expression in response to inflam-
mation, greatly increasing local GC levels [21]. This
increase in local activation of physiological GCs exerts
anti-inflammatory effects, supporting the resolution of
acute inflammation. However, during chronic inflamma-
tion, GCs generated by 11β-HSD1may be insufficient to
drive normal resolution and, instead, persist at elevated
levels, contributing to tissue damage [22].
The regulation and functional consequences of
11β-HSD1 expression within muscle during inflam-
mation have not yet been explored. This has particular
relevance in chronic inflammation, where endogenous
GC may possess a dual function, suppressing the effects
of proinflammatory signalling and protecting against
inflammatory myopathy, while augmenting mecha-
nisms that mediate GC-induced muscle wasting. We
therefore evaluated the effects of 11β-HSD1 activity on
factors that regulate muscle physiology, and examined
responses to inflammation in vitro and in vivo, by using
a murine model of systemic inflammation in which
the human proinflammatory cytokine tumour necrosis
factor (TNF)-α is expressed in all tissues, to dissect the
relationship between local activation of physiologically
relevant levels of GCs and inflammation.
Materials and methods
Human TNF-α transgenic (TNF-Tg) mouse model
and clinical scoring
Experiments were performed according to strict
guidelines governed by the UK Animal (Scientific
Procedures) Act 1986 (project licence number 70/8582
or 70/8003), and were approved by the Birmingham
Ethical Review Subcommittee. Tg197 mice (TNF-Tg)
were obtained from G Kollias (BSRC Fleming, Athens,
Greece) [23]. At 5–6weeks of age, heterozygous
TNF-Tg mice develop spontaneous systemic chronic
inflammation. Mice were scored three times weekly
for body weight, paw swelling, and systemic inflam-
matory features. Clinical scores were calculated by
scoring weight loss, behaviour, mobility, duration of
joint swelling, mouse grimace, and evidence of joint
inflammation (supplementary material, Table S1). At
9weeks, mice were killed, and quadriceps and tibialis
anterior muscle groups were collected. Heterozygous
TNF-Tg mice were crossed with mice with global dele-
tion of 11β-HSD1 to generate homozygous 11β-HSD1
null mice that were heterozygous for the TNF-Tg
transgene [24].
Primary human muscle biopsies
Following ethical approval (UK National Research
Ethics Committee 14/ES/1044), patients with hip
osteoarthritis (OA) (age 69± 3 years, Kellgren–
Lawrence grade 3/4; n= 9) were recruited prior to
elective joint replacement surgery. Between 150 and
200mg of quadriceps muscle was collected at the
time of surgery, and snap-frozen in liquid nitrogen or
collagenase-digested to isolate myoblasts.
Primary human muscle culture
Reagents were obtained from Sigma (Gillingham, UK)
unless stated otherwise. Primary myoblasts (CC-2580;
Lonza, Slough, UK) were maintained in house in
Skeletal Muscle Basal Medium-2 (Lonza; CC-3244 and
CC-3246) containing 0.1% human epidermal growth
factor, 2% L-glutamine, 10% fetal bovine serum (FBS)
and 0.1% gentamicin/amphotericin-B in the absence of
GCs. Confluent myotubes were differentiated in Dul-
becco’s modified Eagle’s medium (DMEM) containing
2% horse serum (HS) for 120 h. Media were replaced
every 2–3 days [25].
Primary murine muscle cell culture
Primary cultures of differentiated myotubes were
generated from murine tibialis anterior muscles as
previously described [26]. In brief, whole tibialis
anterior muscles were removed from wild-type (WT)
C57/Bl6 mice at 9weeks, and digested by type 1
collagenase at 37 ∘C for 2 h before isolation of indi-
vidual fibres. Fibres were plated in 2ml of muscle
expansion medium [DMEM High Glucose, 30%
FBS, 10% HS, 1% chick embryo extract (CEE), and
10 ng/ml basic fibroblast growth factor] and grown in
plates coated with Matrigel (Corning Life Sciences,
Corning, NY, USA) (diluted 1:40 in DMEM High
Glucose). Satellite cells migrating from muscle fibres
were removed and cultured in maintenance medium
(DMEM High Glucose 10% HS, 0.5% CEE) until
confluent. Primary myoblasts were differentiated in
selective medium (DMEM High Glucose, 2% HS) for
5 days until syncytialized myotubes formed.
Analysis of mRNA abundance
The levels of expression of specific mRNAs were
determined with TaqMan Gene Expression Assays
(Thermo Fisher Scientific, Loughborough, UK). RNA
was extracted from mature myotubes and muscle biop-
sies (50mg) with a single-step TRI Reagent extraction
method. Aliquots (1 μg) of RNA were reverse tran-
scribed by the use of random hexamers according to
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the manufacturer’s protocol (4311235, Multiscribe;
ThermoFisher Scientific). The levels of 11β-HSD1
(HSD11B1), H6PDH and GRα (NR3C1) mRNAs
were assessed to determine the expression of genes
that impact on GC activation. FBXO32, TRIM63 and
FOXO1 mRNAs were measured as markers of atrophy,
IGF1, IGF2 and IRS1 mRNAs as anabolic markers,
MYOD1, MYF5, MYF6 and MYOG mRNAs as mark-
ers of differentiation, MSTN mRNA as a catabolic
marker, and GILZ, IL6 and TNF mRNAs as inflam-
matory markers. These and their murine counterparts
were assessed with species-specific probe sets by
real-time polymerase chain reaction (PCR) on an
ABI7500 system (Applied Biosystems, Warrington,
UK). Final reactions contained 2× TaqMan PCR mas-
termix (Thermo Fisher Scientific, Loughborough, UK),
200 nmol of TaqMan probe, and 25–50 ng of cDNA.
The abundance of specific mRNAs in a sample was
normalized to that of 18S RNA. Data were obtained
as Ct values, and used to determine ΔCt values (Ct
target – Ct 18S). Gene expression in arbitrary units
(AU) was calculated from ΔCt values with the equation
1000×−2ΔCt.
Immunohistochemistry
Immunohistochemistry was performed on paraffin
sections of human quadriceps muscle isolated from
patients with OA, as previously described [27]. In
brief, sections were incubated with rabbit polyclonal
antibodies against 11β-HSD1 (1:50, 10007815, Lot
no. 0452916; Cayman, Ann Arbor, Michigan, USA),
and then with goat anti-rabbit biotin as a secondary
antibody (1:1000, AB360; The Binding Site, Birm-
ingham, UK). Antigen retrieval was performed with
0.2× trypsin in 1% (w/v) calcium chloride for 30min
at room temperature and blocking with 10% goat
serum. Sections were incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:1000;
Dako, Glostrup, Denmark) before visualization by
incubation with 3,3′-diaminobenzidine (Vector Labora-
tories, Burlingame, CA, USA) until development of a
brown precipitate (5min).
Histological analysis of muscle
Histochemistry was performed on paraffin-embedded
10-μm sections of murine muscle biopsies isolated from
the quadriceps muscles of WT, TNF-Tg, 11β-HSD1
knockout (11βKO) and TNF-Tg/11βKO mice. Sections
were stained with haematoxylin and eosin prior to
quantitative analysis of fibre size and number in three
200-μm2 regions of the vastus medialis from six mice
per group with Image J software.
11β-HSD1 activity
Confluent cells and tissues were cultured in medium
containing either 100 nmol/l cortisone or 100 nmol/l
DHC (to measure oxoreductase/activation activity)
along with tritiated tracer amounts of cortisone or
corticosterone (Perkin Elmer, Beaconsfield, UK).
Steroids were extracted with dichloromethane and
separated by thin-layer chromatography with ethanol/
chloroform (8:92) as the mobile phase. Thin-layer
chromatography plates were analysed with a Bioscan
imager (Bioscan, Washington, DC, USA), and the frac-
tional conversion of steroids was calculated. The protein
concentration was determined with the Bio-Rad Protein
assay by use of the Bradford method (1-800-424-6723;
Bio-Rad, Hercules, CA, USA), and sample concentra-
tions were calculated from a known standard curve.
Experiments were performed in triplicate, and results
are expressed as pmol product per mg protein.
Multiplex cytokine analysis
Levels of interleukin (IL)-1β, IL-1rα, IL-4, IL-8, IL-10,
IL-17A, interferon (IFN)-γ, monocyte chemotactic
protein 1 (monocyte chemotactic and activating fac-
tor), macrophage inflammatory protein-1α and TNF-α
in conditioned culture medium of primary human
myotubes were measured simultaneously by the use
of Bio-Plex, Pro Human, Luminex MagPlex beads,
according to the manufacturer’s protocol (12001660
and 12001671; Bio-Rad). In brief, culture medium was
collected from primary human myotubes (generated
as above) following treatment with either 10 ng/ml
TNF-α, 100 nmol/l cortisol, and 100 nmol/l cortisone,
with or without 1 μmol/l LJ2 (PF-877423). Sam-
ples were analysed with a Luminex plate reader and
Starstation software (Applied Cytometry Systems,
Sheffield, UK).
MTT viability assay
CellTiter 96 (Promega, Southampton, UK) was used
to determine the number of viable cells in murine and
human primary myotube cultures (generated as above)
following treatment with either the murine or human
inactive GC precursor (100 nmol/l DHC or cortisone,
respectively). Following 5 days in medium containing
either vehicle control or inactive GC, cells were washed
and incubated with medium containing 20% CellTiter
96 reagent. Plates were incubated at 37 ∘C for 50min,
after which absorbance was measured at 490 nm with a
Victor3 multilabel counter (Perkin Elmer).
Statistical analysis
Unless stated otherwise, data are shown as
mean± standard error (SE) of the mean for muscle
biopsies and primary cultures derived from at least
three independent mice or OA patients; animal studies
were performed on six mice per experimental group
(Table 1). Statistical significance was defined as a
p-value of <0.05 obtained with either an unpaired Stu-
dent’s t-test or two-way ANOVA with Dunnett’s post hoc
analysis as appropriate. Throughout, sample sizes are
presented as N, denoting numbers of independent mice
and patients within a group, and n, denoting numbers of
independent cell cultures derived from different donors.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 472–483
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
11𝛃HSD1 protects against local inflammation within muscle 475
Table 1. Numbers of samples assessed. (A) Numbers of
osteoarthritis (OA) patients who donated muscle biopsies to the
study, and the respective numbers in this cohort utilized in ex vivo
biopsy and primary culture experiments. (B) Total numbers of mice
per group [wild type (WT), tumour necrosis factor-α transgenic
(TNF-Tg), 11β-hydroxysteroid dehydrogenase type 1 knockout
(11βKO), and TNF-Tg/11βKO) utilized in ex vivo biopsy and primary
culture experiments
(A) OA patient
quadriceps biopsies
(total= 9)
(B) Mice per group
(WT, TNF-Tg,
11KO, TNF-Tg/11KO)
(total= 6)
Tissue type
Ex vivo
biopsy
Primary
culture
Ex vivo
biopsy
Primary
culture
11β-HSD1 activity 3 3 6 3
mRNA analysis 3 3 6 3
Histology 3 NA 6 NA
Cytokine analysis NA 3 6 3
Fibre diameter NA 3 6 3
Cell viability NA 3 NA 3
NA, not applicable, as experiment not performed.
Statistical analysis of reverse transcription-quantitative
PCR (RT-qPCR) data was carried out on ΔCt values.
Results
TNF-α-driven chronic inflammation elevates
11β-HSD1 expression at sites of inflammatory
muscle wasting
The expression and activity of 11β-HSD1 are upreg-
ulated at sites of inflammation [28,29]. However,
relatively little is known about how this enzyme is
regulated by inflammation within muscle. We examined
11β-HSD1 expression and activity in muscles from
a transgenic mouse model of chronic TNF-α-driven
systemic inflammation (TNF-Tg).
In this model, TNF-α overexpression is driven via
removal of the 3′-untranslated region (UTR) from the
TNF gene, and its subsequent replacement with the
3′-UTR of the β-globin gene (HBB), greatly increasing
TNF mRNA transcriptional efficiency, stability and
expression in all tissues, including muscle [23]. At
5–6weeks of age, TNF-Tg mice develop a progressive
systemic inflammatory phenotype, with paw swelling,
polyarthritis, and weight loss (Figure 1A). In biopsies
of tibialis anterior and quadriceps muscle, 11β-HSD1
mRNA expression, and the ability to generate cor-
ticosterone from its inactive precursor DHC, were
significantly increased in TNF-Tg mice relative to WT
littermate controls (mRNA, 2.7-fold, p< 0.005; activity,
1.7-fold, p< 0.05) (Figure 1B, C). These data provide
the first evidence that 11β-HSD1 expression is upregu-
lated in muscle in vivo by TNF-α-driven inflammation.
TNF-α potently induces local cortisol generation
in human muscle
To determine whether comparable inflammatory regu-
lation of 11β-HSD1 occurs within human muscle, we
utilized biopsies of quadriceps muscles from OA
patients, and also generated primary cultures of
differentiated myotubes from human cells sourced
commercially.
Myoblasts were differentiated for 5 days in selective
medium until cells underwent syncytialization, forming
myotubes that spanned culture plates (Figure 2A).
These were then cultured in maintenance medium for
72 h. Expression of the muscle differentiation marker
myogenin was significantly increased in differentiated
cultures (36-fold relative to undifferentiated control,
p< 0.0005) (Figure 2B). Incubation of fully differ-
entiated primary myotubes with TNF-α (10mg/ml)
resulted in significant increases in 11β-HSD1 mRNA
expression and cortisol synthesis (mRNA, 7.6-fold,
p< 0.005; activity, 4.1-fold, p< 0.005) (Figure 2C, D).
We have previously demonstrated that TNF-α regulates
11β-HSD1 in mesenchymal-derived cells via nuclear
factor-κB (NF-κB) signalling. Therefore, we examined
this pathway in in myotubes by using the inhibitor
of NF-κB signalling Mln-4924 (2 μM) [30]. Whereas
11β-HSD1 mRNA expression was strongly induced at
2 h by 10 ng/ml TNF-α (five-fold increase, p< 0.005),
this induction was abrogated by the selective NF-κB
inhibitor (Figure 2E). Thus, the induction of 11β-HSD1
by TNF-α in muscle is regulated through the NF-κB
pathway.
Next, we examined the basal expression of 11β-HSD1
and its regulation by TNF-α in muscle biopsies from
OA patients. 11β-HSD1 was expressed throughout
human muscle fibres (Figure 2F). To better delineate
the relevance of in vitro findings to muscle ex vivo,
we examined 11β-HSD1 expression and its inflamma-
tory regulation by TNF-α by using quadriceps muscle
biopsies (Figure 2G). Basal mRNA expression of
11β-HSD1 was observed, with significant induction by
TNF-α (10 ng/ml) at 6 and 16 h [4.2-fold (p< 0.005)
and 9.6-fold (p< 0.005) increase relative to samples
at baseline, respectively]. Therefore, in both human
myotube cultures and in ex vivo human muscle biopsies,
11β-HSD1 was potently upregulated by TNF-α. This
suggests that human muscle has the capacity to respond
to acute inflammatory stressors by increasing local
GC production. Next, we assessed the significance and
functional consequences of elevated endogenous GC
production within muscle during inflammation.
Locally activated GCs suppress proinflammatory
cytokine production in primary myotube culture
Given the upregulation of 11β-HSD1 expression and
activity within muscle following inflammatory stim-
ulation, we assessed the functional consequences of
raised intramuscular endogenous GC levels in primary
myotube cultures.
IL-6 was examined as a cytokine that is potently
upregulated in response to TNF-α in mesenchymal-
derived cells. In murine muscle culture, the endogenous
corticosterone precursor DHC strongly reduced IL6
mRNA levels (9.3-fold, p< 0.005) (Figure 3A), whereas
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Figure 1. (A) Clinical scoring of behaviour, mobility, weight loss, mouse grimace, evidence of joint inflammation and duration of joint
swelling (as outlined in supplementary material, Table S2) in TNF-Tg and WT littermate controls between 5 and 9weeks of age (N = 6 per
group). (B) mRNA abundance (AU) of 11β-HSD1 determined by RT-qPCR in tibialis anterior muscles isolated from TNF-Tg and WT controls
at 9weeks (N = 6 per group). (C) Rate of corticosterone generation by ex vivo biopsies of whole quadriceps muscles isolated from TNF-Tg
and WT controls following incubation for 16 h with DHC, determined by scanning thin-layer chromatograms (N = 6 per group). Values are
expressed as mean± SE. Statistical significance was determined with Student’s unpaired t-test. *p< 0.05, **p< 0.005, ***p< 0.0005.
expression of the anti-inflammatory GC response gene
GILZ was significantly increased (Figure 3B). These
effects were abrogated by the selective 11β-HSD1
inhibitor LJ2. Similar observations were made in
primary human myotube culture, with the inactive
precursor cortisone having similar effects on both IL6
and GILZ mRNA expression as the active GC corti-
sol (IL6, 7.1-fold decrease, p< 0.005; GILZ, 2.6-fold
increase, p< 0.005) (Figure 3C, D). When primary
human myotube cultures were preincubated with
TNF-α to induce 11β-HSD1 activity, similar patterns
of IL6 and GILZ expression were found in response
to cortisone (Figure 3E, F). However, the absolute
cortisone suppression of IL6 mRNA was significantly
greater in TNF-α-prestimulated myotubes than in
vehicle-treated controls (30-fold greater suppression
of IL6 in TNF-α-prestimulated myotubes; p< 0.0005)
(Figure 3G). The effects of cortisone were entirely
blocked in the presence of the selective 11β-HSD1
inhibitor LJ2 in the TNF-α-pretreated human myotube
culture (Figure 3E, F).
We then examined the cytokine profiles of pri-
mary human myotubes following incubation with
cortisone (Figure 3H–J). The expression levels of the
proinflammatory cytokines IL-6, TNF-α and IFN-γwere
all significantly reduced following treatment with cor-
tisone (IL-6, 18.6% decrease, p< 0.05; TNF-α, 12.7%
decrease, p< 0.05; IFN-γ, 21% decrease, p< 0.05);
these effects were abrogated by the selective 11β-HSD1
inhibitor LJ2.
For the first time, we have demonstrated that upreg-
ulation of 11β-HSD1 by TNF-α influences the inflam-
matory profiles of both murine and human primary
myotubes, suppressing proinflammatory cytokine out-
put and enhancing GILZ signalling.
Locally activated GCs suppress anabolic and induce
catabolic pathways in murine, but not human,
muscle culture
Previous studies have shown that prolonged exposure
to supraphysiological levels of GCs results in muscle
wasting in vivo and increased atrophy of myotubes and
catabolic breakdown of protein in vitro. Consequently,
we examined the effects of endogenous GCs on mRNA
levels of genes central to these processes, includ-
ing MYOG, IGF1, and FOXO1. In murine primary
myotubes, expression of the catabolic factor gene
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Figure 2. (A) Representative images of undifferentiated primary myoblasts isolated from human quadriceps. Primary myoblasts syncytialize
over a 5-day differentiation period in selective medium, forming primary myotubes in vitro. (B) Fold change in mRNA expression of the
muscle differentiation gene MYOG in undifferentiated human myoblasts and mature mytotubes at day 5 after differentiation, determined
by RT-qPCR (n= 3 per group). (C, D) mRNA expression of the 11β-HSD1 gene (C) and the rate of generation of cortisol from cortisone (D)
in differentiated human myotubes over a period of 16 h following 24 h of pretreatment with TNF-α (10 ng/ml), determined by RT-qPCR
and scanning thin layer chromatograms, respectively (n= 3 per group). (E) mRNA expression of the 11β-HSD1 gene in differentiated
human myotubes following treatment with TNF-α (10 ng/ml) for 2 h in the presence or absence of the selective NF-κB signalling inhibitor
Mln-4924 at 2 μM (n= 3 per variable). (F) Paraffin sections of quadriceps muscles isolated from OA patients were stained for 11β-HSD1
by immunohistochemistry, and counterstained with Gill’s haematoxylin (N = 3) (scale bars: 50 μm). (G) Gene expression (AU) of 11β-HSD1
was measured by RT-qPCR in ex vivo OA quadriceps biopsies following incubation with TNF-α (10 ng/ml) for either 0, 3, 6 or 16 h (N = 3
per variable). Values are expressed as mean± SE. Statistical significance was determined with using Student’s unpaired t-test (B–D) and
one-way ANOVA with a Dunnett post hoc analysis (E, G). **p< 0.005, ***p< 0.0005.
Mstn was significantly increased (1.8-fold, p< 0.05),
that of the anabolic signalling factor gene Igf1 was
significantly suppressed (1.37-fold, p< 0.05) and that
of the atrophy marker gene Trim63 was significantly
increased (1.4-fold, p< 0.05) by the GC precursor
DHC at 100 nmol/l (Figure 4A–C). These effects were
abrogated by selective 11β-HSD1 inhibition. Analysis
of a panel of differentiation, anabolic, catabolic and
atrophy genes, includingMyog,Myod1, Foxo1, Fbxo32,
Trim63, Igf1, and Igf2, revealed no additional genes
that were responsive to endogenous levels of GCs
(supplementary material, Figure S2). Exposure to DHC
for 5 days resulted in a significant reduction in murine
myotube fibre size and reduced cell viability (Figure 4D,
E). These effects were not observed in primary human
myotubes exposed to cortisone, either in the absence
of TNF-α or after induction of 11β-HSD1 by TNF-α
(Figure 4F–J; supplementary material, Figure S1).
These data provide evidence that locally activated
endogenous GCs increase muscle wasting through
the 11β-HSD1 enzyme in murine muscle in vitro. In
contrast, the actions of endogenous GCs were less
conclusive in the human in vitro model, with no func-
tional evidence that they mediate muscle wasting being
obtained.
Global deletion of 11β-HSD1 results in pronounced
muscle wasting in the TNF-Tg mouse
To delineate the contribution of inflammatory
11β-HSD1 expression and GC activation to muscle
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Figure 3. (A, B) Gene expression (AU) of Il6 and Gilz in murine primary cultures of differentiated myotubes isolated from WT quadriceps
biopsies (n= 3 per variable). Cultures were incubated for 16 h with either the inactive corticosterone precursor DHC (100 nmol/l), the
selective 11β-HSD1 inhibitor LJ2 (1000 nmol/l), or a combination of the two. (C–G) Gene expression (AU) of IL6 and GILZ in human primary
cultures of differentiated myotubes isolated from quadriceps muscles (n= 3 per variable). Cultures were stimulated with either vehicle (C, D)
or TNF-α (E, F) at 10 ng/ml for 48 h (n= 3 per variable). Cultures were then maintained in medium containing either vehicle control, cortisol
(100 nmol/l), the inactive corticol precursor cortisone (100 nmol/l), the selective 11β-HSD1 inhibitor LJ2 (1000 nmol/l) or a combination of
both cortisone and inhibitor for 16 h. (G), The decrease in IL6 mRNA level relative to respective vehicle controls following incubation with
cortisone in the vehicle and TNF-α-prestimulated groups was then measured (n= 3 per variable). (H–J) Concentrations of IL-6, TNF-α and
IFN-γwithin 48-h conditioned medium of primary human myotubes treated with either control, cortisol (100 nmol/l), cortisone (100 nmol/l),
or LJ2 (1000 nmol/l) and cortisone, determined by multiplex cytokine analysis (n= 3 per variable). Values are expressed as mean± SE.
Statistical significance was determined with one-way ANOVA with a Dunnett post hoc analysis. *p< 0.05, **p< 0.005. LJ2= PF-877423.
inflammation and muscle wasting in vivo, we generated
a TNF-α-driven murine model (TNF-Tg) of muscle
wasting on a global 11β-HSD1 null (TNF-Tg/11βKO)
background.
TNF-Tg/11βKO mice presented with a more rapid
onset of systemic inflammation than TNF-Tg mice
(Figure 5A). Examination of quadriceps and tibialis
anterior muscles confirmed a complete absence of
endogenous 11β-HSD1-mediated GC activation in
TNF-Tg/11βKO mice (Figure 5B). When normalized
for body weight, TNF-Tg/11βKOmice had significantly
reduced quadriceps weights relative to age-matched
TNF-Tg mice (TNF-Tg, 10.2± 0.75mg/g total body
weight; TNF-Tg/11βKO, 7.49± 0.43mg/g total body
weight; p< 0.0005) (Figure 5C). Histological analysis
of muscle in TNF-Tg/11βKO mice revealed smaller
fibres than those from their TNF-Tg, 11βKO and WT
counterparts (Figure 5D). No significant inflammatory
infiltrates were evident within muscle biopsies from
TNF-Tg or TNF-Tg/11βKO mice, indicating this phe-
notype was not underpinned by invading leukocytes.
Examination of muscle fibres in TNF-Tg/11βKO mice
confirmed that the average fibre diameter was signifi-
cantly reduced relative to TNF-Tg mice (3.1± 0.26AU
versus 4.1± 0.21AU, respectively; p< 0.005), driven
by an increase in the number of small fibres and a reduc-
tion in the number of large fibres (Figure 5E–G). The
number of fibres with centralized nuclei was consistent
between groups, indicating that the phenotype was not
driven by increased generation of fibres, as is observed
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Figure 4. Levels of mRNA in primary cultures of differentiated myotubes isolated from quadriceps muscle biopsies from WT mice (A–C) and
human quadriceps biopsies (F–H) (n= 3 per variable), determined by RT-qPCR. To induce 11β-HSD1 expression, human primary cultures
were pretreated with TNF-α (10 ng/ml) for 48 h prior to a 12-h washout. Cells were then incubated for 16 h with either control, active cortisol
(100 nmol/l), or its inactive precursor cortisone (100 nmol/l). In murine culture, cells were treated for 24 h with either control medium, the
inactive corticosterone precursor DHC (100 nmol/l), or DHC in combination with the selective 11β-HSD1 inhibitor LJ2 (1000 nmol/l). Fibre
width and cell viability were determined with Image J analysis software and MTT assay, respectively, in murine (D, E) and human (I, J) primary
myotubes following incubation with normal control medium and DHC (100 nmol/l)-containing medium over a period of 5 days (n= 3 per
variable). Values are expressed as mean± SE. Statistical significance was determined with one-way ANOVA with a Dunnett post hoc analysis.
*p< 0.05, **p< 0.005.
in conditions of increased muscle turnover and repair.
Instead, these data suggest increased inflammatory wast-
ing in TNF-Tg/11βKOmice relative to their TNF-Tg and
WT counterparts. Examination of anabolic, catabolic,
differentiation and muscle atrophy genes (supplemen-
tary material, Figure S2) failed to identify significant
changes between TNF-Tg and TNF-Tg/11βKO mice,
despite elevated expression of human TNF-α mRNA
within muscle (Figure 5H). In contrast, gene expression
levels of both endogenous murine TNF-α and IL-6 were
markedly increased in TNF-Tg/11βKO mice relative to
their TNF-Tg counterparts (IL-6, 13.2-fold, p< 0.005;
TNF-α, 2.1-fold, p< 0.05) (Figure 5I, J). Consequently,
given the increased severity of the wasting phenotype
in the absence of 11β-HSD1, this model suggests that,
instead of contributing to inflammatory muscle wast-
ing, endogenously generated GCs protect against the
deleterious effects of excess inflammation in muscle.
Discussion
The actions of therapeutic and endogenous GCs are
closely regulated by the tissue-specific actions of the
GC-activating enzyme 11β-HSD1. We examined the
role of 11β-HSD1 in muscle during inflammation, and
assessed whether increased activation of physiologically
relevant levels of endogenous GCs influences inflamma-
tion associated muscle loss.
We have previously reported that 11β-HSD1 activity
is potently upregulated by proinflammatory cytokines
such as TNF-α and IL-1β within mesenchymal cells,
such as osteoblasts, adipocytes, dermal fibroblasts,
and stromal fibroblasts [21,22,29,31]. In this study, we
demonstrate that 11β-HSD1 activity is potently upregu-
lated through the NF-κB signalling pathway by TNF-α
in human primary muscle cultures, in human muscle
ex vivo, and in vivo in a TNF-α-driven murine model
of chronic inflammation and muscle wasting. Given the
importance of 11β-HSD1 in mediating tissue-specific
responsiveness to GCs, the marked upregulation with
inflammation raises important questions regarding its
role in muscle during inflammation.
In the context of non-muscle cells, such as syn-
ovial fibroblasts, we previously reported that GCs
activated by 11β-HSD1 suppress proinflammatory
signalling [22,29]. Furthermore, 11β-HSD1 is critical
in mediating the resolution of inflammation in murine
models of peritonitis and acute polyarthritis [22,32,33].
Despite these protective anti-inflammatory actions,
GCs contribute to muscle wasting when administered
in excess. Consequently, we focused on how, within
muscle, the endogenous physiologically relevant levels
of GCs activated by 11β-HSD1 influence markers of
muscle metabolism, atrophy and differentiation, and
inflammation.
We found, as previously reported in murine myotube
culture, that extended exposure to endogenous GCs acti-
vated by 11β-HSD1 resulted in a shift in IGF-1 and
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Figure 5. (A) Clinical scoring of behaviour, mobility, weight loss, mouse grimace, evidence of joint inflammation and duration of joint
swelling (as outlined in supplementary material, Table S2) in TNF-Tg/11βKO mice versus TNF-Tg controls between 5 and 9weeks of age
(N = 6 per group). (B) Rate of corticosterone generation by ex vivo biopsies of whole quadriceps muscles isolated from WT, TNF-Tg, 11βKO
and TNF-Tg mice on an 11βKO background following incubation for 16 h with DHC, as determined by scanning thin-layer chromatograms
(N = 6 per group). (C) Total quadriceps muscle weight normalized to total body weight in WT, TNF-Tg, 11βKO and TNF-Tg mice on an 11βKO
background (N = 6 per group). (D) Representative images of quadriceps muscle sections taken from WT and 11βKO mice on either control
or TNF-Tg backgrounds stained with Gill’s haematoxylin and eosin (scale bars: 50 μm) (N = 6 per group). (E–G) Average fibre size (AU),
and quantification of small (<30 μm) and large (≥20 μm) fibres (AU) determined with Image J in paraffin sections of quadriceps muscles
isolated from WT mice, TNF-Tg mice, and TNF-Tg mice on an 11βKO background (N = 6 per group). (H–J) Levels of mRNA (ΔCt) for human
TNF-α and the murine proinflammatory genes Il6 and Tnf in WT mice, TNF-Tg mice and TNF-Tg mice on an 11βKO background at 9weeks
(N = 6 per group). Values are expressed as mean± SE. Statistical significance was determined with one-way ANOVA with a Dunnett post hoc
analysis. ND, not detected; NS, not significant. *p< 0.05, **p< 0.005, ***p< 0.0005.
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myostatin gene expression, favouring catabolic mus-
cle breakdown. This correlated with increased lev-
els of markers of atrophy, and resulted in decreased
myotube fibre size and viability. However, unlikemurine
myotubes, primary human myotube cultures were rel-
atively resistant to the actions of physiologically rel-
evant concentrations of GCs generated by 11β-HSD1,
with there being nomarked change inmetabolic, atrophy
or differentiation genes either in the presence or in the
absence of TNF-α. It is important to note that the trans-
lational relevance of murine models to human disease is
often contested. In this study, we observed differences in
endogenous GC action on muscle wasting between pri-
mary human and murine muscle cultures. This indicates
a need for further characterization of these differences
in future studies utilizing these in vitro models.
The actions of proinflammatory cytokines and the
NF-κB pathway have been shown to be integral to
inflammatory muscle wasting, mediated in part through
their regulation of the ubiquitin proteasome system
[34–38]. Many of the anti-inflammatory actions of GCs
are mediated through suppression of signalling path-
ways such as AP-1 and NF-κB, resulting in the suppres-
sion of downstream inflammatory mediators [39,40].
When we examined markers of proinflammatory sig-
nalling, we observed that endogenous GCs activated by
11β-HSD1 potently suppressed IL-6, IFN-γ and TNF-α
expression in both primary murine and human muscle
culture. Given the known role of these proinflammatory
cytokines in the inflammatory muscle wasting process,
the effects of GCs generated by 11β-HSD1 were seen
to be overwhelmingly anti-inflammatory and potentially
muscle-sparing.
Taken together, these findings indicate dual effects
of endogenous GCs generated by 11β-HSD1 during
inflammation; although they drive muscle wasting
via well-defined GC-mediated wasting pathways,
11β-HSD1 also mediates potent anti-inflammatory
effects of GCs that may be muscle-sparing. To ascer-
tain which of these 11β-HSD1-mediated effects
predominates in muscle in vivo, in the context of
chronic inflammatory muscle wasting, we utilized the
TNF-Tg transgenic mouse (TNF-Tg), on an 11β-HSD1
global null background (TNF/11βKO). Having demon-
strated that human TNF-α is upregulated to a similar
extent in both the TNF-Tg and TNF/11βKO mice, we
explored whether TNF/11βKO mice would be spared
11β-HSD1-mediated GC muscle wasting during muscle
inflammation, or whether the loss of inflammation
suppression by 11β-HSD1-generated GCs would exac-
erbate inflammatory muscle loss. In our model, the
absence of endogenous GC generation by 11β-HSD1 in
the TNF-Tg mouse did not abrogate or reverse inflam-
matory muscle wasting. Instead, these mice developed
significantly greater muscle loss, with smaller muscles
and muscle fibres.
These effects correlated with significantly higher
levels of proinflammatory gene expression in muscle
than in TNF-Tg controls in the absence of infiltrating
leukocytes. Given the well-recognized role of these
proinflammatory cytokines in mediating muscle wast-
ing, it is likely that the loss of their suppression, in the
absence of 11β-HSD1, exacerbates inflammatory mus-
cle wasting. Although increased leukocyte infiltration
driven by suppression of 11β-HSD1 within muscle can
be ruled out as a primary factor, it should be noted that,
given the global nature of this null model, changes in
inflammatory output by immune cells at distant loca-
tions or in local stromal populations cannot be ruled out
as contributing to this wasting phenotype. Although it
has been reported that endogenous GCs play a role in
the differentiation of mesenchymal-derived cells such
as myoblasts, we observed no shift in the expression
of differentiation markers from TNF-Tg/11βKO mice
that would underpin this phenotype through reduced
myogenesis (supplementary material, Figure S2) [41].
Furthermore, 11βKO mice retain a normal muscle
phenotype without evidence of reduced myoblast differ-
entiation, suggesting that circulating GCs are sufficient
for basal muscle differentiation in these animals [42].
Consequently, these data suggest a more important
role for 11β-HSD1 in modifying inflammation within
muscle, protecting against muscle wasting by sup-
pressing the expression of proinflammatory cytokines
and targeting the immunomodulatory and immuno-
suppressive actions of endogenous GCs locally within
muscles, as reported previously in skin [43]. In contrast
to the protective action of endogenous GCs in inflam-
matory muscle wasting in vivo in our murine model,
we observed effects consistent with muscle wasting in
vitro in murine primary muscle culture. Consequently,
when interpreting in vitro studies, it must be recognized
that they may not fully reproduce the more complex
inflammatory environment conditions seen in vivo.
Despite this, given the interest in the therapeutic tar-
geting of 11β-HSD1 to manage metabolic complica-
tions arising from inflammatory diseases, these data
provide valuable insights into possible muscle-related
complications.
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